GALT

Galectin Therapeutics (GALT)

About Galectin Therapeutics (GALT)

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Details

Daily high

$2.63

Daily low

$2.56

Price at open

$2.62

52 Week High

$4.27

52 Week Low

$1.56

Market cap

163.8M

Dividend yield

0.00%

Volume

16,050

Avg. volume

134,686

P/E ratio

-3.36

Galectin Therapeutics News